MESQUITE, NV / ACCESSWIRE / December 21, 2016 / Cannabis Sativa, Inc. (CBDS) announced that on December 20, 2016, the company's subsidiary was awarded Patent PP27,475 for a Cannabis Plant named "Ecuadorian Sativa".
"Equadorian Sativa" has been shown in laboratory testing by Steephill Labs to have a Limonene level that is extraordinarily high at a level of 4.53, 10 to 20 times the usual range. This sets "Equadorian Sativa" apart from other varieties in its odor, the effects on mood and mentation and its medical qualities.
The objective of the breeding, which produced this novel plant strain nicknamed "CTA", was primarily to develop a plant having the following characteristics: (a) medicinal properties that included hypotensive activity; (b) psychoactive properties that motivated and energized, rather than creating lethargy, sleepiness, and (c) increased food consumption.
Anecdotally, there are indications that its use may prevent some cancers and may cause apoptosis of cancer cells in vivo. There is a good possibility that the high levels of limonene may slow down the build-up of plaque in the arteries and reduce the effect of low-density lipo-proteins on the circulatory system. Indications are that "Ecuadorian Sativa" has many medical qualities that make it an important tool to maintain health and deal with illness.
"Our patience is now rewarded with the issuance of Patent PP27,475". "This patent will open up new areas for research and opportunities for CBDS", said CEO Mike Gravel.
This plant was derived from a female said to be of a strain called colloquially, "Celestial Temple Sativa" an individual grown in Ecuador that as a solitary plant reached a height of 23 feet. The male parent is said to have been of a strain known colloquially as "Island Sweet Skunk".
The Company's President David Tobias said, "This is a major accomplishment and is a tribute to the foresight and perseverance of management to solidify Cannabis Sativa's contribution to the maturing Cannabis industry."